Management of Symptomatic Hyperandrogenism in Young Adult Female with PCOS
Start with combination oral contraceptive pills as first-line therapy for symptomatic hyperandrogenism (hirsutism, acne) in young adult women with PCOS, and add an antiandrogen agent (spironolactone) if oral contraceptives alone provide insufficient symptom control. 1
First-Line Pharmacologic Management
Combination Oral Contraceptive Pills
Oral contraceptive pills are the primary treatment for hyperandrogenic symptoms in PCOS based on ACOG guidelines 1. They work through two mechanisms:
- Suppress ovarian androgen secretion
- Increase sex hormone-binding globulin (SHBG), which reduces free testosterone levels
The evidence shows OCPs significantly increase SHBG (by 103.30 nmol/L compared to placebo) 2, making them highly effective for managing clinical hyperandrogenism. Use low-dose preparations to minimize metabolic side effects 1.
Combined Medical Therapy for Resistant Cases
If oral contraceptives alone fail to adequately control hirsutism or acne, add an antiandrogen agent 1. The combination of an antiandrogen plus ovarian suppression (OCP) is more effective than either alone 1.
Antiandrogen options include:
- Spironolactone (most commonly used)
- Flutamide (reduces DHEAS by 0.37 µg/dL) 2
- Finasteride
The specific choice of antiandrogen is based on consensus and expert opinion, as no single agent has proven superior 1.
Important Caveats
FDA-Approved Topical Therapy
Topical eflornithine hydrochloride cream is the only FDA-labeled medication specifically for hirsutism 1. However, its additional benefits or risks in PCOS remain unknown. Use this as an adjunct to systemic therapy, not as monotherapy.
Concomitant Mechanical Hair Removal
Medical management alone is often insufficient. Patients typically require concurrent mechanical hair removal (shaving, waxing, laser, or electrolysis) 1. Importantly:
- Laser vaporization and electrolysis require multiple treatments
- Medical therapy to reduce androgen levels should continue during mechanical treatments
- Electrolysis is impractical for large areas
Metabolic Considerations
Insulin-Sensitizing Agents
While metformin reduces total testosterone (SMD: -0.33) 2 and improves metabolic parameters 1, it has limited or no benefit for treating hirsutism or acne 3. Reserve metformin for:
- Patients with documented insulin resistance or prediabetes
- Menstrual irregularity management
- Metabolic syndrome features
Do not use metformin as primary therapy for symptomatic hyperandrogenism 3.
Weight Loss as Adjunctive Therapy
Even 5% weight loss improves metabolic and reproductive abnormalities in PCOS 1. While the direct effect on hyperandrogenic symptoms is uncertain, weight loss provides broader health benefits and should be recommended alongside pharmacologic therapy 1.
Treatment Algorithm
- Initiate low-dose combination oral contraceptive pill
- Assess response at 3-6 months
- If inadequate symptom control: Add antiandrogen (spironolactone preferred)
- Consider topical eflornithine for facial hirsutism as adjunct
- Recommend mechanical hair removal methods concurrently
- Add metformin only if: metabolic abnormalities present (insulin resistance, prediabetes, metabolic syndrome)
Critical Pitfalls to Avoid
Do not use insulin-sensitizing agents as monotherapy for hyperandrogenic symptoms - they lack efficacy for hirsutism and acne despite reducing androgen levels 3.
Do not delay combination therapy - waiting to see if OCPs alone work for 6-12 months before adding antiandrogens unnecessarily prolongs patient distress. If symptoms are severe, start combination therapy immediately 1.
Do not use thiazolidinediones - they have an unfavorable risk-benefit ratio overall in PCOS 3, and one agent (troglitazone) was removed from market due to hepatotoxicity 1.
Screen for contraindications to OCPs including cardiovascular risk factors, though no evidence suggests increased cardiovascular events with OCP use specifically in PCOS patients compared to general population 1.
Evidence Quality Note
The recommendations for combined antiandrogen plus OCP therapy are based primarily on consensus and expert opinion rather than high-quality randomized trials 1. However, this represents the best available evidence and is endorsed by ACOG guidelines. The evidence for OCPs alone is stronger, based on good and consistent scientific evidence 1.